Novo Nordisk A/S
AI, excess weight decline medicine and additional: Portfolio manager names stocks to perform ‘new secular progress themes’
Marketplaces may well be dealing with an “unconventional total” of uncertainty, but there continue to are really fantastic chances ideal, in accordance to a single portfolio supervisor, who tells CNBC Professional about three new expansion spots and the shares he likes. There are numerous “cross currents” in the industry correct now, claimed Sanjay Ayer of […]
Read More
Wall Street hikes forecasts for anti-obesity drug sales to $100 billion and beyond — A look at the numbers
Most analysts predict the market for new weight loss drugs like Wegovy and Mounjaro will be enormous, but estimates vary for its exact size depending on who you ask. On Monday, Citi raised its estimate for incretin drug sales to $71 billion by 2035, up from its prior estimate of $55 billion. That viewpoint seems […]
Read More
These stocks are trying to solve a major shortcoming of weight loss drugs: Shrinking muscle mass
One of the downsides of taking new anti-obesity medications is that patients tend to lose lean muscle mass along with body fat. What this means for patients over the long term isn’t fully known, but there are several pharmaceutical companies studying the side effect and hoping to develop therapies that might regulate the condition. In […]
Read More
Sanofi to offer insulin product for $35 to all Americans through GoodRx
Sanofi Lantus brand insulin pens are arranged for a photograph in the Brooklyn borough of New York, U.S., on Friday, April 5, 2019. Alex Flynn | Bloomberg | Getty Images Americans, regardless of their insurance status, can now access Sanofi‘s most widely prescribed insulin for $35 through the prescription drug savings company GoodRx, the companies […]
Read More
GLP-1 pounds reduction medicine are making prospects for these 2 stocks, investment advisor claims
GP1-1 (glucagon-like peptide-1) medicines, initially made as a therapy for diabetic issues, are shaking up some sectors. Developments encompassing the prescription drugs, also commonly made use of for fat decline, have been disrupting anything at all from owners of dialysis facilities to bariatric medical procedures providers and the foodstuff marketplace. But just one financial investment […]
Read More
CNBC Professional Talks: Munro Partners’ Nick Griffin to examine AI, Significant Tech and stocks to short
Artificial intelligence shares have been on a tear this 12 months, but is it too late to spend? Sign up for CNBC’s Will Koulouris as he quizzes Nick Griffin, chief investment decision officer of Munro Associates, on the AI concept, Big Tech, and how to enjoy shares this sort of as Nvidia and Microsoft . Submit […]
Read More
‘Miracle drug’ euphoria: Specialists warn widespread use of fat decline medicine faces main hurdles
Two gurus see key difficulties facing the adoption of new being overweight medicine. Dr. Kavita Patel, a physician and NBC News health-related contributor, thinks new knowledge from Novo Nordisk on Ozempic’s means to hold off the development of long-term kidney disease is among the strongest supporting proof for secondary uses of the drug. On the […]
Read More
Many are betting Ozempic will reduce the need for knee surgery. What it means if they’re wrong
Medical device stocks of all kinds were pummeled over the past week as investors tried to calculate the ripple effects of new weight loss drugs. It wasn’t the first rout in the sector — the pressure has persisted for several months. The fear has been that whenever you have a large group of consumers changing […]
Read More
Novo Nordisk hikes outlook on soaring demand for Wegovy, Ozempic
An Ozempic (semaglutide) injection pen is seen on a kitchen table in Riga, Latvia on 06 August, 2023. Jaap Arriens | Nurphoto | Getty Images Novo Nordisk on Friday raised its outlook for its full-year sales and operating profit due to soaring demand for its blockbuster weight loss drug Wegovy and diabetes treatment Ozempic. The […]
Read More
LVMH shares tumble to 2023 small as growth slows, pulling luxury sector down
A LVMH Moet Hennessy Louis Vuitton SE store in Shanghai, China on Wednesday, June 14, 2023. Bloomberg | Bloomberg | Getty Illustrations or photos Shares of LVMH dropped to their least expensive amount of the yr on Wednesday morning, just after the corporation reported a slowdown in income progress that was beneath anticipations. The stock […]
Read More